Literature DB >> 2310341

Nasolacrimal duct obstruction after endoscopic sinus surgery.

C L Serdahl1, C E Berris, R A Chole.   

Abstract

Intranasal endoscopic sinus surgery has several potential ocular complications, including visual loss, diplopia, retrobulbar hemorrhage, and epiphora. We treated eight patients with persistent nasolacrimal duct obstruction after endoscopic sinus surgery. All patients required dacryocystorhinostomy to achieve a patent lacrimal system drainage. To our knowledge, this is a previously unreported complication in the ophthalmologic literature. The relevant anatomy of the nasolacrimal duct is discussed in addition to surgical procedures for avoidance and treatment of iatrogenic injury to the system. Endoscopic sinus surgery is a highly successful procedure that is rapidly gaining popularity among otolaryngologists. As the number of patients undergoing this type of surgery increases, an increase in the relative number of ocular complications should be anticipated.

Entities:  

Mesh:

Year:  1990        PMID: 2310341     DOI: 10.1001/archopht.1990.01070050089038

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Swing door technique for uncinectomy versus standard technique: a comparative study.

Authors:  Samar Pal Singh Yadav; Kuljeet Singh; Joginder Singh Gulia; Anita Hooda
Journal:  Singapore Med J       Date:  2019-12-10       Impact factor: 1.858

2.  Evaluation of the effect of inferior turbinate outfracture on nasolacrimal transit time by saccharin test.

Authors:  Kerem Kökoğlu; Alperen Vural
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-15       Impact factor: 2.503

3.  Endoscopic dacryocystorhinostomy as treatment for lower lacrimal pathway obstructions in adults: Review article.

Authors:  Elina Penttilä; Grigori Smirnov; Henri Tuomilehto; Kai Kaarniranta; Juha Seppä
Journal:  Allergy Rhinol (Providence)       Date:  2015-01

4.  Uncontrolled systemic hypertension and haemolacria.

Authors:  G Seethapathy; Jitendra Jethani
Journal:  Indian J Ophthalmol       Date:  2020-04       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.